Interim HY Financial Report & Appendix 4D
| Stock | Skin Elements Ltd (SKN.ASX) |
|---|---|
| Release Time | 27 Feb 2026, 2:41 p.m. |
| Price Sensitive | Yes |
Skin Elements Reports Interim HY Financial Results
- Revenues decreased 41.23% to $183,984
- Loss from ordinary activities after tax increased 232.50% to $4,010,205
- Net tangible assets increased to $1,580,573
Skin Elements Limited (ASX: SKN) reported its interim financial results for the half-year ended 31 December 2025. Revenues from ordinary activities decreased 41.23% to $183,984, while loss from ordinary activities after tax increased 232.50% to $4,010,205. The loss includes a non-cash accounting loss of $3,302,376 from the settlement of $1,000,000 of Director liabilities via shares and options. The company's net tangible assets increased to $1,580,573 as at 31 December 2025. Skin Elements continued to focus on the development and commercialization of its proprietary SE Formula technology, including the SuprCuvr hospital-grade disinfectant, ECO-Nurture plant bio-stimulant, Soléo Organics sunscreen, PapayaActivs therapeutics skincare, and Elizabeth Jane Natural Cosmetics brand. The company completed a $2.5 million capital raising and repaid $433,256 previously advanced by Radium Capital against its R&D Rebate. Subsequent to the reporting period, the company appointed two new Non-Executive Directors and one director retired.